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Abstract
Background: Unstable angina (UA) patients have lower mortality and reinfarction risks than ST-elevation
(STEMI) or non-ST elevation myocardial infarction (NSTEMI) patients and, accordingly, receive less
aggressive treatment. Little is known, however, about the health status outcomes (angina, physical
function, and quality of life) of UA versus MI patients among survivors of an ACS hospitalization.
Methods: In a cohort of 1,192 consecutively enrolled ACS survivors from two Kansas City hospitals, we
evaluated the associations between ACS presentation (UA, NSTEMI, and STEMI) and one-year health
status (angina, physical functioning and quality of life), one-year cardiac rehospitalization rates, and two-
year mortality outcomes, using multivariable regression modeling.
Results: After multivariable adjustment for demographic, hospital, co-morbidity, baseline health status,
and treatment characteristics, UA patients had a greater prevalence of angina at 1 year than STEMI patients
(adjusted relative risk [RR] = 1.42; 95% CI [1.06, 1.90]) and similar rates as NSTEMI patients (adjusted RR
= 1.1; 95% CI [0.85, 1.42]). In addition, UA patients fared no better than MI patients in Short Form-12
physical component scores (UA vs. STEMI score difference -0.05 points; 95% CI [-2.41, 2.3]; UA vs.
NSTEMI score difference -1.91 points; 95% CI [-4.01, 0.18]) or Seattle Angina Questionnaire quality of life
scores (UA vs. STEMI score difference -1.39 points; 95% CI [-5.63, 2.85]; UA vs. NSTEMI score difference
-0.24 points 95% CI [-4.01, 3.54]). Finally, UA patients had similar rehospitalization rates as MI patients
(UA vs. STEMI adjusted hazard ratio [HR] = 1.31; 95% CI [0.86, 1.99]; UA vs. NSTEMI adjusted HR = 1.03;
95% CI [0.73, 1.47]), despite better 2-year survival (UA vs. STEMI adjusted HR = 0.51; 95% confidence
interval (CI) [0.28, 0.95]; UA vs. NSTEMI adjusted HR = 0.40; 95% CI [0.24, 0.65]).
Conclusion: Although UA patients have better survival rates, they have similar or worse one-year health
status outcomes and cardiac rehospitalization rates as compared with MI patients. Clinicians should be
aware of the adverse health status outcome risks for UA patients and consider close monitoring for the
opportunity to improve their health status and minimize the need for subsequent rehospitalization.
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Background
Acute coronary syndrome (ACS) clinical presentations,
including ST-elevation myocardial infarction [STEMI],
non-ST-elevation myocardial infarction [NSTEMI], and
unstable angina [UA], are associated with different mor-
tality and recurrent myocardial infarction (MI) rates [1-4].
Accordingly, optimal ACS management, as outlined in the
American College of Cardiology/American Heart Associa-
tion guidelines, stratifies and treats patients differently
according to their presentation so that those with the
greatest mortality risk receive the most aggressive therapy
[1,5-8]. However, mortality and rehospitalization are not
the only clinically important outcomes. Patient health sta-
tus outcomes, including their symptom burden, func-
tional status, and health-related quality of life, are critical
outcomes from the patient's perspective [9-12]. Accord-
ingly, patient health status has recently been advocated as
a marker of healthcare quality [13-15].
Despite its clinical importance, little is known about the
association between ACS presentation and health status
outcomes, especially among UA patients. Given that
many cardiac patients are initially identified during an
ACS presentation, characterizing this association from the
perspective of this presentation is essential to better prog-
nosticate and treat patients with symptomatic coronary
disease. Accordingly, we evaluated one-year health status
outcomes in a consecutive cohort of ACS patients as a
function of their clinical presentation. Identifying patients
at risk for poorer health status could identify the need for
improved methods of risk stratification so as to improve
care and outcomes in ACS patients.
Methods
Study population and design
The Investigation oF Outcomes from acute coRonary syn-
droMes (INFORM) registry is a prospective, observational
cohort study of consecutively hospitalized ACS patients at
two Kansas City hospitals, the Mid America Heart Insti-
tute and Truman Medical Center, to identify determinants
of health status outcomes among ACS survivors. It was
powered for minimal detectable differences of >5 points
in SAQ quality of life (disease perception) and angina fre-
quency scores. In total, 10,911 consecutive hospitalized
patients who had a troponin blood test performed at
either hospital between March 2001 and October 2002
were prospectively screened for a possible ACS. 1199
patients with confirmed ACS (see definitions below) were
enrolled in the registry (Figure 1) and underwent detailed
interviews and chart abstractions to obtain their socio-
demographic, health status, clinical, and treatment char-
acteristics. All data elements conformed to the standards
established in the American College of Cardiology Task
Force on Clinical Data Standards[16]. Since our investiga-
tion focused on those who survived to hospital discharge,
those patients who died during hospitalization (n = 7; 3
STEMI, 3 NSTEMI, and 1 UA) were excluded from the
analyses. One year after their index hospitalization, fol-
low-up phone interviews were conducted to collect health
status and rehospitalization information. Each participant
Flowchart of screened and enrolled patients in the INFORM registry Figure 1
Flowchart of screened and enrolled patients in the INFORM registry.
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signed an informed consent to participate in this study
and Institutional Review Board approval from both insti-
tutions (Saint Luke's Health System Institutional Review
Board and the University of Missouri-Kansas City Adult
Health Sciences Institutional Review Board) was obtained
prior to the conduct of the study.
Acute coronary syndrome classification
Standard definitions were used to confirm patients' ACS
diagnosis [17]. STEMI patients presented with suggestive
cardiac symptoms, diagnostic electrocardiogram (EKG)
changes (ST segment elevation or new-onset left bundle
branch block [LBBB]), and a positive troponin blood test
(during the course of this investigation, the following
assays and thresholds were used by the enrolling centers:
cTroponin-I assay >0.15 ng/mL, Advia-Centaur, Bayer
Diagnostics, Tarrytown, NY; cTroponin-I assay >0.05 ng/
mL, Dade Dimension RXL, Dade Behring Diagnostics,
Deerfield, IL; cTroponin-I assay >1.9 ng/mL, Abbott Labs,
Abbott Park, IL). NSTEMI patients presented with sugges-
tive cardiac symptoms and/or EKG changes (e.g. ST seg-
ment depressions and/or T wave changes), and a positive
troponin blood test. UA patients presented with sugges-
tive cardiac symptoms, as defined by at least one of the
following: new onset angina (<2 months) of at least Cana-
dian Cardiovascular Society Classification (CCSC) class
III, prolonged (>20 minutes) rest angina, recent (<2
months) worsening of angina, or angina that occurred
within 2 weeks of a previous MI [18]. Although EKG
changes were not a requirement for diagnosis, nearly one-
half of UA patients had ischemic EKG changes on admis-
sion (LBBB 4%, ST-elevations 9%, ST-depressions 12%, T-
wave inversions 22%). By definition, all UA patients had
a negative troponin blood test. To further increase the spe-
cificity of the unstable angina diagnosis, those patients
with a diagnostic study that excluded obstructive coronary
disease, cardiac perfusion defects, or segmental wall
motion abnormalities (e.g. coronary angiography, nuclear
or echocardiographic stress testing) (n = 125) or con-
firmed an alternative explanation for their presentation
(e.g. esophagogastroduodenoscopy) were excluded. Three
physicians reviewed the charts of all patients for whom
diagnostic uncertainty (n = 45) remained and attained
consensus on the final diagnosis.
Health status, rehospitalization, and mortality assessment
After excluding expired patients by querying the Social
Security Death Master File, surviving patients underwent
follow-up telephone interviews to obtain one-year rehos-
pitalization rates and health status outcomes. Health sta-
tus outcomes were measured using the Seattle Angina
Questionnaire (SAQ) and the Short Form-12 Version 2
(SF-12). The SAQ is a 19-item disease-specific health sta-
tus measure for patients with coronary artery disease
(CAD) that has well-established validity, reliability, sensi-
tivity to clinical change, and prognostic value [13,19-22].
Five domains are assessed: anginal frequency, anginal sta-
bility, physical limitation, treatment satisfaction, and dis-
ease perception. The scales used in these analyses range
from 0–100, where higher scores indicate fewer symp-
toms and higher quality of life. The SF-12 is a generic
health status measure that is converted into physical and
mental component scores [23]. A score of 50 reflects the
United States' population mean, and a deviation of 10
points reflects 1 standard deviation from that mean.
Higher scores indicate better physical and mental func-
tioning.
We measured the health status outcomes of symptoms,
physical functioning, and health-related quality of life
with the SAQ angina frequency scale, the SF-12 physical
component scale, and the SAQ disease perception scale,
respectively. The SAQ scales of treatment satisfaction and
angina stability were less informative to our research
question, and thus not analyzed. In addition, the SF-12
physical functioning scale was used instead of the SAQ
physical limitation scale because the SF-12 scale was more
representative of activities that registry patients performed
and the disease-specific SAQ created more missing data
for physical function than did the SF-12. One-year cardiac
rehospitalization rates were collected by patient self-
report at the follow-up interview. Hospitalizations for
chest pain, heart failure, myocardial infarction (MI), car-
diac revascularization (percutaneous coronary interven-
tion [PCI], or coronary artery bypass graft [CABG]) were
defined as cardiac. Hospitalizations for other reasons were
coded as non-cardiac. Two-year mortality data was deter-
mined by querying the Social Security Administration
Death Master File. A final query of the Social Security
Death Master File, hospital and outpatient records for
vital status and hospitalization data was performed in
October 2004.
Statistical analysis
After categorizing patients by their ACS presentation
(STEMI, NSTEMI and UA), baseline clinical characteristics
were compared. Categorical data were reported as fre-
quencies, and differences were assessed using chi-square
tests. Continuous data were reported as means ± standard
deviations and differences were assessed using analysis of
variance.
To evaluate the independent association between ACS
presentation and outcomes, multivariable models were
created to adjust for all other differences in socio-demo-
graphic (age, race, sex, and insurance status), hospital
(Mid-America Heart Institute or Truman Medical Center),
clinical (prior MI, prior PCI, prior CABG, congestive heart
failure, hypertension, diabetes, hyperlipidemia, cerebrov-
ascular accident/transient ischemic attack, renal failure,BMC Cardiovascular Disorders 2007, 7:28 http://www.biomedcentral.com/1471-2261/7/28
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anemia, and tobacco use), baseline physical function or
quality of life (SF-12 physical functioning scores or SAQ
quality of life scores) and treatment (both revasculariza-
tion (PCI, CABG, or thrombolysis) and discharge medica-
tions (angiotensin converting enzyme [ACE] inhibitors,
lipid lowering agents, beta-blockers, calcium channel
blockers, nitrates, and aspirin)) characteristics. Anemia
was defined as hemoglobin values less than the fifth per-
centile of the sex, race, and age-matched population [24].
Categories of variables (socio-demographic, site, clinical,
baseline health status, and treatment) were entered
sequentially into the model and presented accordingly, in
order to illustrate the additive effects of each variable
group on the various outcomes.
SAQ angina frequency scores were modeled as a dichoto-
mous outcome of any angina vs. no angina at one year
after index ACS hospitalization because of the skewed
nature of the measure and our clinical goal of seeking to
completely eliminate patients' angina [25]. Since one-year
angina in our study was a relatively frequent event, we
estimated adjusted relative risks directly using a modified
Poisson regression model, rather than using logistic
regression which estimates adjusted odds ratios [26]. SF-
12 physical component and SAQ quality of life scores
were modeled as continuous variables using multivariable
linear regression. Model diagnostics were conducted using
residual and normal probability plots.
Unadjusted differences in mortality and rehospitalization
rates between ACS classes were described graphically with
Kaplan-Meier survival plots and compared using the log-
rank test. Adjusted differences in mortality and rehospital-
ization rates between ACS classes, using the same covari-
ates as the health status models, were compared using
multivariable Cox proportional hazards regression mod-
els. Cox proportional hazards assumptions were tested
using Schoenfeld residuals.
All analyses were performed with SAS version 9.3.1 (SAS
Institute, Inc., Cary, NC) and R version 2.1.1 (R Develop-
ment Core Team. R: A Language and Environment for Sta-
tistical Computing. Vienna, Austria). Statistical
significance for all analyses was assumed when the p value
was less than 0.05. Scheffe correction techniques for mul-
tiple comparisons were used for pair-wise comparisons.
Missing data
Among the 1192 patients who survived until hospital dis-
charge, 77 (6.5%) died within 12 months of follow-up.
Health status outcomes were not imputed for those who
died. Thus, our health status results characterize those
who survived for at least one year after discharge. Among
survivors, 210 patients (17.6%) were not interviewed at
one year, because they could not be contacted (73% of
non-respondents), or refused to complete the interview
(27% of non-respondents). Among those lost-to-follow-
up patients, there were no significant differences by ACS
presentation.
We explored potential selection biases in the rehospitali-
zation and health status outcomes through the use of sen-
sitivity and propensity model analyses. Sensitivity
analysis was performed by imputing poor health status
scores to those patients (n = 22) who were too ill to par-
ticipate in the follow-up interview. Specifically, patients
were assigned a SAQ Angina Frequency score indicating
presence of angina, an SF-12 physical functioning score of
25, and a SAQ quality of life score of 50; the lowest deciles
for each outcome. Regression analyses were repeated
using these imputed values and no statistically or clini-
cally significant differences in results were noted (results
not shown).
As an alternative approach for handling missing health
status data from patients who refused 1-year interviews or
could not be contacted, propensity scores were computed
using non-parsimonious multivariable logistic regression
models to predict the likelihood of unsuccessful follow-
up [27]. Predictor variables included all available demo-
graphic, socio-economic and lifestyle factors, clinical
characteristics, vital signs and laboratory studies, disease
severity, baseline health status, medication, acute, and
non-acute treatments received during patients' initial ACS
hospitalization. From these models, a probability of suc-
cess for completing an interview was calculated. The recip-
rocal of this probability was then assigned to those
patients' scores in the multivariable regression analyses in
order to assess for potential observable bias from those
lost to follow-up by weighting patients that are similar to
those with missing data more heavily [27]. These analyses
also demonstrated that the missing patients did not
impact our primary findings. In light of the consistency of
our findings with both imputation and propensity
approaches for handling missing data, we have presented
only the primary results.
Results
Patient characteristics by ACS presentation
Among the 1192 ACS survivors, 318 (27%) presented
with STEMI, 355 (30%) with NSTEMI, and 519 (44%)
with UA. Table 1 illustrates the socio-demographic and
clinical characteristics, baseline health status scores, revas-
cularization therapies and discharge medications for each
ACS class. Demographically, NSTEMI patients were more
likely to be older than either STEMI or UA patients, STEMI
patients were more likely to be male than either NSTEMI
or UA patients, and STEMI patients were more likely to be
white compared to UA patients. Clinically, UA patients
had significantly higher rates of prior cardiac disease, asBMC Cardiovascular Disorders 2007, 7:28 http://www.biomedcentral.com/1471-2261/7/28
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indicated by prior myocardial infarction and revasculari-
zation, as compared with both STEMI and NSTEMI
patients. In addition, UA patients had significantly worse
physical functioning and poorer quality of life on admis-
sion than either STEMI or NSTEMI patients.
Treatments also differed by ACS classification. STEMI
patients had the highest revascularization rates and UA
patients the lowest (86.3% and 42.0%, respectively). Sig-
nificant differences in discharge medication prescriptions
were also observed. STEMI and NSTEMI patients were
more likely to be treated with beta-blockers at discharge,
while UA patients received higher rates of ACE-inhibitors,
calcium-channel blockers, and nitrates (Table 1).
Mortality and rehospitalization outcomes
UA patients had the lowest two-year mortality rates, but
similar one-year rehospitalization rates. At two years, 25
(7.9%) STEMI patients and 45 (12.8%) NSTEMI patients
had died as compared with only 35 (6.7%) UA patients
(log-rank p-value 0.006; Figure 2a). After multivariable
analysis controlling for socio-demographic, site, clinical,
Table 1: Demographic and clinical characteristics by ACS presentation
Variables STEMI NSTEMI UA ANOVA
n = 321 n = 358 n = 520 p-value
Demographics
Age 60.8 +/- 12.5 63.2 +/- 13.0 * 61.0 +/- 13.0 ‡ p = 0.023
Male 70.7% 56.7% * 59.6% † p < 0.001
Caucasian 85.3% 81.6% 76.5% † p = 0.08
Insured 84.4% 89.4% 85.6% p = 0.132
Employed (full or part-time) 46.3% 36.9% * 34.6% † p = 0.02
Past medical history
History of myocardial infarction 22.1% 24.3% 44.4% †‡ p < 0.001
History of percutaneous coronary intervention 21.8% 27.7% 46.2% †‡ p < 0.001
History of coronary artery bypass graft 10.0% 18.4% * 25% †‡ p < 0.001
Congestive heart failure 3.7% 7.8% * 8.5% † p = 0.027
Hypertension 56.4% 63.4% 72.7% †‡ p < 0.001
Diabetes mellitus 19.6% 24.6% 32.7% †‡ p < 0.001
Hyperlipidemia 51.1% 58.1% 68.3% †‡ p < 0.001
Transient ischemic attack 1.2% 1.7% 2.1% p = 0.65
Cerebrovascular accident 0.9% 2.5% 2.7% p = 0.208
Chronic obstructive pulmonary disease/asthma 5.6% 12.8% § 12.9% † p = 0.001
Renal failure 0.9% 2.0% 2.7% p = 0.214
Anemia 62.2% 61.7% 50.2% p < 0.001
Tobacco use 68.2% 69.9% 73.2% †‡ p < 0.001
Baseline health status
SAQ angina rates 95.0% 87.4% * 93.1% ‡ p < 0.001
SF-12 physical component scores 42.7 +/- 11.4 39.1 +/- 12.3 * 35.3 +/- 11.9 †‡ p < 0.001
SAQ quality of life scores 50.4 +/- 17.3 53.4 +/- 20.2 * 47.0 +/- 18.8 †‡ p < 0.001
ACS therapies
Primary reperfusion 86.3% 65.1% * 42% †‡ p < 0.001
Percutaneous coronary intervention 63.9% 62% § 40.8% †‡ p < 0.001
Lysis 22.4% 3.1% § 1.2% †‡ p < 0.001
Coronary artery bypass graft 4.4% 3.9% 2.9% p < 0.001
Discharge meds
Angiotensin converting enzyme inhibitors 18.1% 30.2% * 36.5% †‡ p < 0.001
Lipid lowering 79.8% 77.7% 75.2% p = 0.191
Beta-blockers 87.5% 84.4% 72.5% †‡ p < 0.001
Calcium channel blockers 10.0% 14.2% 23.7% †‡ p < 0.001
Nitrates 9.3% 12.0% 18.1% †‡ p < 0.001
Acetylsalicylic acid (aspirin) 95.9% 93.9% 92.7% p = 0.379
*STEMI v NSTEMI p-value < 0.05; †STEMI v UA p-value < 0.05; ‡NSTEMI v UA p-value < 0.05; ANOVA, analysis of variance; NSTEMI, non-ST-
elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable angina; SAQ, Seattle Angina Questionnaire; SF-12, Short 
Form 12BMC Cardiovascular Disorders 2007, 7:28 http://www.biomedcentral.com/1471-2261/7/28
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and treatment characteristics, UA patients had signifi-
cantly lower mortality rates compared to STEMI and
NSTEMI patients (UA vs. STEMI hazard ratio (HR) = 0.51;
95% confidence interval (CI) [0.28, 0.95]; UA vs. NSTEMI
HR = 0.40; 95% CI [0.24, 0.65]) (Figure 2b). At one year,
102 (26.6%) UA patients were rehospitalized for cardiac
causes, as compared to 43 (17.6%) STEMI patients and 60
(23.3%) NSTEMI patients (log-rank p-value 0.035: Figure
3a). After multivariable adjustment, UA patients had sim-
ilar one-year cardiac rehospitalization rates to STEMI and
NSTEMI patients (UA vs. STEMI HR = 1.31; 95% CI [0.86,
1.99]; UA vs. NSTEMI HR = 1.03; 95% CI [0.73, 1.47]; Fig-
ure 3b).
Health status outcomes
One year after discharge, UA patients had worse unad-
justed angina rates, physical component scores, and qual-
ity of life scores than either STEMI or NSTEMI patients
(Figure 4a–c). After sequential multivariable adjustment
for all covariates, UA patients were more likely to experi-
ence angina than STEMI patients (UA vs. STEMI angina
relative risk (RR) = 1.42; 95% CI [1.06, 1.90]). Adjusted
angina rates between UA and NSTEMI were similar (UA
vs. NSTEMI angina RR = 1.10; 95% CI [0.85, 1.42]) (Fig-
ure 4a), as were the remainder of health status scores
between all three ACS classes (UA vs. STEMI adjusted
mean physical component score difference = -0.05 points,
95% CI [-2.41, 2.30]; UA vs. NSTEMI adjusted mean phys-
ical component score difference = -1.91 points, 95% CI [-
4.01, 0.18]; UA vs. STEMI adjusted mean quality of life
score difference = -1.39 points, 95% CI [-5.63, 2.85]; UA
vs. NSTEMI adjusted mean quality of life score difference
= -0.24 points, 95% CI [-4.01, 3.54]) (Figure 4b,c).
Discussion
Although previous studies have documented higher mor-
tality among MI patients as compared to those with UA
[1-3], none have systematically evaluated the association
of ACS presentation with health status outcomes. Our
study is the first to illustrate that UA patients have a higher
prevalence of angina at 1 year than STEMI patients, even
after adjustment for numerous differences in patient char-
acteristics and treatment. Furthermore, we found that, in
contrast to their better prognosis in terms of survival, UA
patients had a similar prevalence of angina as compared
with NSTEMI patients and similar one-year physical func-
tioning scores, quality of life scores, and cardiac rehospi-
talization rates to both STEMI and NSTEMI patients. Our
study suggests that since UA patients' favorable prognosis
with respect to mortality does not translate to health sta-
tus outcomes, close follow-up and monitoring of UA
patients is needed.
With the recognition of MI patients' elevated mortality
risk, the medical community substantially reorganized
itself, resulting in community interventions to accelerate
the recognition and treatment of potential MIs, emer-
gency department chest pain centers for rapid patient
triage, increased access to primary PCI, early institution of
anti-platelet treatments and invasive risk stratification,
resulting in impressive mortality reductions over the past
decades [4,7,28-33]. However, the results of this study
highlight the adverse health status outcome risks present
in the UA population, as compared with MI patients.
Given that these are critical outcomes for patients and
providers alike, clinicians should be aware of these risks
and should develop interventions to improve the health
status outcomes of UA patients.
One previous report has also noted poorer health status
outcomes among UA patients. Rumsfeld and colleagues
evaluated 2733 ACS patients, using a general health status
instrument, the Short Form-36 (SF-36), and followed
patients for 7 months after their index hospitalization.
They found that a discharge diagnosis of UA, as compared
with MI, was associated with a worse SF-36 physical com-
ponent score [34]. Our study strengthens and extends
these initial findings by using a cardiac disease-specific
instrument, assessing a broader range of health status out-
comes (including angina and health-related quality of life
in addition to physical functioning), adjusting for a
greater number of potential confounders, and conducting
observations over a longer follow-up period.
Several characteristics of the UA population may partially
explain their worse angina outcomes. The high prevalence
of pre-existing CAD and low revascularization rates
among UA patients may contribute to their higher angina
rates and lower health status scores, though adjustment
for these factors did not eradicate the higher angina rates
of UA patients compared to STEMI patients [35,36]. Other
unmeasured characteristics of their care, such as less
intensive outpatient medical and/or revascularization
therapies, decreased medical follow-up, and decreased
medication adherence among UA patients, may affect
patients' long-term health status and represent important
opportunities to improve their outcomes. Further research
is needed to evaluate the outpatient care of ACS patients
so that greater insights into the potential opportunities to
improve the angina rates among UA patients may be
uncovered.
Multiple studies have demonstrated improvements in
anginal symptoms and subsequent health status among
CAD patients with both medical therapy and revasculari-
zation, though most studies document greater health sta-
tus improvements with revascularization strategies as
compared to standard medical therapy [37-42].
Mortensen and colleagues noted improved three-year
angina rates and SF-36 physical functioning scores amongBMC Cardiovascular Disorders 2007, 7:28 http://www.biomedcentral.com/1471-2261/7/28
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(a) Unadjusted Kaplan-Meier survival curves of two-year mortality by ACS presentation Figure 2
(a) Unadjusted Kaplan-Meier survival curves of two-year mortality by ACS presentation (b) Unadjusted and sequential adjust-
ment of two-year mortality by ACS presentation (Model 1 = unadjusted comparison; Model 2 = adjustment for demographic 
variables (age, race, sex, insurance status); Model 3 = adjustment for demographic and hospital site variables (Mid-America 
Heart Institute or Truman Medical Center); Model 4 = adjustment for demographic, site, and clinical variables (prior angina, 
prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, congestive heart fail-
ure, hypertension, diabetes, hyperlipidemia, cerebrovascular accident/transient ischemic attack, renal failure, anemia and 
tobacco use); Model 6 = adjustment for demographic, site, clinical, and treatment (revascularization [percutaneous coronary 
intervention, coronary artery bypass graft, thrombolysis] and discharge medications [angiotensin converting enzyme inhibitors, 
lipid lowering agents, beta-blockers, calcium channel blockers, nitrates, and aspirin]) variables)
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(a) Unadjusted Kaplan-Meier survival curves of one-year cardiac rehospitalization by ACS presentation Figure 3
(a) Unadjusted Kaplan-Meier survival curves of one-year cardiac rehospitalization by ACS presentation (b) Unadjusted and 
sequential adjustment of one-year cardiac rehospitalization by ACS presentation (Model 1 = unadjusted comparison; Model 2 = 
adjustment for demographic variables (age, race, sex, insurance status); Model 3 = adjustment for demographic and hospital 
site variables (Mid-America Heart Institute or Truman Medical Center); Model 4 = adjustment for demographic, site, and clini-
cal variables (prior angina, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass 
graft, congestive heart failure, hypertension, diabetes, hyperlipidemia, cerebrovascular accident/transient ischemic attack, renal 
failure, anemia and tobacco use); Model 6 = adjustment for demographic, site, clinical, and treatment (revascularization [percu-
taneous coronary intervention, coronary artery bypass graft, thrombolysis] and discharge medications [angiotensin converting 
enzyme inhibitors, lipid lowering agents, beta-blockers, calcium channel blockers, nitrates, and aspirin]) variables)
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(a) Unadjusted and sequential adjustment of one-year angina by ACS presentation Figure 4
(a) Unadjusted and sequential adjustment of one-year angina by ACS presentation (b) Unadjusted and sequential adjustment of 
one-year physical functioning by ACS presentation (c) Unadjusted and sequential adjustment of one-year quality of life by ACS 
presentation (Model 1 = unadjusted comparison; Model 2 = adjustment for demographic variables (age, race, sex, insurance 
status); Model 3 = adjustment for demographic and hospital site variables (Mid-America Heart Institute or Truman Medical 
Center); Model 4 = adjustment for demographic, site, and clinical variables (prior angina, prior myocardial infarction, prior per-
cutaneous coronary intervention, prior coronary artery bypass graft, congestive heart failure, hypertension, diabetes, hyperlip-
idemia, cerebrovascular accident/transient ischemic attack, renal failure, anemia and tobacco use); Model 5 = adjustment for 
demographic, site, clinical, and baseline health status variables (SF-12 physical component score and SAQ quality of life score 
models only); Model 6 = adjustment for demographic, site, clinical, baseline health status (SF-12 physical component score and 
SAQ quality of life score models only), and treatment (revascularization [percutaneous coronary intervention, coronary artery 
bypass graft, thrombolysis] and discharge medications [angiotensin converting enzyme inhibitors, lipid lowering agents, beta-
blockers, calcium channel blockers, nitrates, and aspirin]) variables)
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patients with inducible post-infarction ischemia who
underwent invasive revascularization [37]. Similarly, Kim
and colleagues demonstrated improved one-year angina
rates and higher one-year quality of life scores among
NSTEMI/UA patients randomized to an invasive revascu-
larization treatment strategy [42]. Given the success of
these strategies in improving health status outcomes
among MI and stable CAD patients, randomized studies
of these and other strategies on health status outcomes
among UA patients should be considered. Concurrently,
integration of objective health status assessment into the
care of ACS patients could offer a tool to identify patients
with residual symptoms and to potentially indicate a need
for additional therapy to improve UA patients' rehospital-
ization rates and quality of life.
Our study has several potential limitations. First, it was
conducted at only 2 Midwestern centers, which may limit
the generalizability of our findings to other centers. Sec-
ond, despite follow-up rates greater than 80%, missing
data can potentially introduce bias. Although our sensitiv-
ity and propensity analyses suggested no important differ-
ences, we cannot rule out the possibility of unmeasured
confounding from those patients without follow-up.
Third, cardiac rehospitalization data was assessed by
patient self-report, and thus subject to potential misclassi-
fication and recall bias. However, trained data collectors
conducted phone interviews, thus minimizing this risk.
Finally, we did not have detailed data about the outpa-
tient treatment regimens of our patients, including the fre-
quency of follow-up medical visits or their medication use
over the year after discharge. Further research will need to
define whether the intensity or quality of post-discharge
care differs across the spectrum of ACS patients.
Conclusion
In conclusion, we found that UA patients had a higher
prevalence of angina than STEMI patients and similar
physical functioning, quality of life, and cardiac rehospi-
talization outcomes as compared with both STEMI and
NSTEMI patients one year after ACS presentation. Since
multiple treatments, including medications and revascu-
larization, are available to improve patients' angina, these
findings identify an important potential opportunity for
improving the quality of care for UA patients. Future stud-
ies to evaluate the impact of these interventions specifi-
cally in UA patients are needed. Until then, clinicians
should remain as vigilant for persistent angina, functional
limitations and poor quality of life among UA patients as
they are among MI patients.
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